Agilent Joins AMBIC to Advance Biomanufacturing
04 Abril 2022 - 9:00AM
Business Wire
Support for bioprocess, cell and gene therapy, and Industry 4.0
initiatives
Agilent Technologies Inc. (NYSE: A) announced today that it has
become a member of the Advanced Mammalian Biomanufacturing
Innovation Center (AMBIC). Joining AMBIC demonstrates the company’s
commitment to partnering to support the provision of the next
generation of analytical tools and comprehensive solutions needed
by academic, pharmaceutical, and clinical researchers.
Agilent plays a key role in providing solutions for the
analytical needs of customers in the biopharmaceutical industry.
The increasing prominence of biopharmaceuticals and precision cell
and gene biotherapeutics has prompted the need for more innovative
measurement tools to help bring life-saving drugs and diagnostics
to patients more efficiently and effectively.
“Our customers recognize the need to improve biotherapeutic
manufacturing,” said Darlene Solomon, senior vice president, and
chief technology officer at Agilent. “Working with AMBIC we look
forward to advancing technologies that will help facilitate
impactful improvements in productivity, process, and ultimately
product yield and quality.”
There is a growing need for rapidly assessing critical process
and product quality attributes to support biotherapeutics
manufacturing and facilitate adaptive process controls. Agilent’s
participation in AMBIC will help focus our commitment to bringing
innovative measurement tools for bioprocess development, and
biomolecular, cell and gene -based therapeutics manufacturing
applications. Our advances in automation, machine learning, the
digital lab ecosystem, and support for Industry 4.0 will help
improve biomanufacturing with real-time inline and at-line
analytical tools and solutions for the biopharmaceutical
industry.
AMBIC brings together leading academic and industrial
biotechnologists focused on mammalian cell culture manufacturing.
Its mission is to develop enabling technologies, knowledge, design
tools, and methods that apply and integrate high-throughput and
genome-based technologies to fast-track advanced biomanufacturing
processes. Through systems-level biology analysis, novel cell line
development, bioreactor optimization, and advanced analytics, AMBIC
aims to provide transformative solutions that can lower
biomanufacturing costs and improve bioprocessing efficiency.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insight and innovation that advance the quality of life.
Agilent’s full range of solutions includes instruments, software,
services, and expertise that provide trusted answers to our
customers' most challenging questions. The company generated
revenue of $6.32 billion in fiscal 2021 and employs 17,000 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220404005352/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024